Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06472128 · ClinicalTrials.gov registry record · NA
Novel Digital Application for Patients With Acute Leukemia
A NA study of High Risk Acute Myeloid Leukemia and Primary Refractory Acute Myeloid Leukemia, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 3
- Study locations
NCT06472128: Recruiting NA study of High Risk Acute Myeloid Leukemia and Primary Refractory Acute Myeloid Leukemia, sponsored by Massachusetts General Hospital.
NCT06472128 is a NA study of High Risk Acute Myeloid Leukemia and Primary Refractory Acute Myeloid Leukemia that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 200 participants, below the 728-participant average among 4 other High Risk Acute Myeloid Leukemia trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06472128, a NA study of High Risk Acute Myeloid Leukemia and Primary Refractory Acute Myeloid Leukemia, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.
Primary Outcome
To compare QOL at day +20 between those receiving DREAMLAND versus VITAL WELLNESS as measured by the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leukemia) at day 20. Higher scores on FACT-Leukemia (range 0-176) indicate a better QOL.
Conditions Studied
Interventions
- BEHAVIORAL DREAMLAND
- BEHAVIORAL VITAL WELLNESS
Study Locations (3)
Massachusetts
- Massachusetts General Hospital (MGH) - Boston
North Carolina
- Duke University - Durham
Washington
- Fred Hutchinson Cancer Research Center (FHCRC) - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2030-04-30 |
| Phase | NA |
What NCT06472128 shows while recruiting
NCT06472128 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 4 other High Risk Acute Myeloid Leukemia trials with a reported enrollment target (73% lower).
The record links to 3 conditions, with High Risk Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which DREAMLAND is the first listed.
NCT06472128 reports a single indexed study location in Massachusetts, North Carolina, Washington.
Frequently Asked Questions
What is clinical trial NCT06472128 about?
NCT06472128 is a clinical study titled "Novel Digital Application for Patients With Acute Leukemia". This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.
What is the current status of trial NCT06472128?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-10-21. Estimated completion is 2030-04-30.
What conditions does trial NCT06472128 study?
This clinical trial studies the following conditions: High Risk Acute Myeloid Leukemia, Primary Refractory Acute Myeloid Leukemia, Relapsed Adult Acute Myeloid Leukemia.
What interventions are being tested in trial NCT06472128?
The interventions under investigation include: DREAMLAND (BEHAVIORAL), VITAL WELLNESS (BEHAVIORAL).
Who is sponsoring clinical trial NCT06472128?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06472128 being conducted?
This trial has 3 study locations across Massachusetts, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Risk Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
RECRUITING · NA
-
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
RECRUITING · Phase 1
-
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI